About UCSF Search UCSF UCSF Medical Center

Steven DuBois, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
dubois_steven

Associate Professor, Department of Pediatrics (Pediatric Hematology/Oncology), UCSF

Phone: (415) 476-3831 (voice)
Box 0106, UCSF
San Francisco, CA 94143-0106

View on UCSF Profiles


Education

Swarthmore College Swarthmore, PA, BA, 1992-1996, Chemistry and Psychobiology
University of California, San Francisco School of Medicine, San Francisco, CA, MD, 1996-2000, Medicine
Harvard School of Public Health, Boston, MA, MS, 2005-2007, Epidemiology
University of California, San Francisco School of Medicine, San Francisco, CA, Internship, 2000-2001, Pediatrics
University of California, San Francisco School of Medicine, San Francisco, CA, Residency, 2001-2003, Pediatrics
Dana-Farber Cancer Institute and Children's Hospital, Boston, Boston, MA, Fellowship, 2004-2007, Pediatric Hematology/Oncology


Professional Experience

  • 2003-2004
    Clinical Instructor Department of Pediatrics University of California, San Francisco
  • 2004-2006
    Fellow Division of Pediatric Hematology/Oncology Dana-Farber Cancer Institute and Children's Hospital Boston Harvard Medical School
  • 2006-2007
    Chief Fellow Division of Pediatric Hematology/Oncology Dana-Farber Cancer Institute and Children's Hospital Boston Harvard Medical School
  • 2007-2012
    Assistant Professor Department of Pediatrics Division of Pediatric Hematology/Oncology, University of California, San Francisco
  • 2012-present
    Associate Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California, San Francisco
     

Honors & Awards

  • 1996
    Phi Beta Kappa Academic Honor Society
  • 2000
    Alpha Omega Alpha Medical Honor Society
  • 2007
    American Society of Pediatric Hematology/Oncology Merit Award
  • 2007
    American Society of Clinical Oncology Merit Award
  • 2007
    American Society of Clinical Oncology Young Investigator Award

Selected Publications

  1. Thampi S, Matthay KK, Boscardin WJ, Goldsby R, DuBois SG. Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. Sarcoma. 2014; 2014:902620.
    View on PubMed
  2. Applebaum MA, Thomas DG, Hembrough T, Burrows J, Horvai AE, Lawlor ER, DuBois SG. Comparative evaluation of strategies for quantifying signaling pathway proteins in ewing sarcoma. Appl Immunohistochem Mol Morphol. 2014 Sep; 22(8):593-9.
    View on PubMed
  3. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 1; 32(28):3169-76.
    View on PubMed
  4. Zinter MS, DuBois SG, Spicer A, Matthay K, Sapru A. Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. Intensive Care Med. 2014 Jul 15.
    View on PubMed
  5. Polishchuk AL, Li R, Hill-Kayser C, Little A, Hawkins RA, Hamilton J, Lau M, Tran HC, Strahlendorf C, Lemons RS, Weinberg V, Matthay KK, DuBois SG, Marcus KJ, Bagatell R, Haas-Kogan DA. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):839-45.
    View on PubMed
  6. Kersten E, Scanlan P, Dubois SG, Matthay KK. Current treatment and outcome for childhood acute leukemia in Tanzania. Pediatr Blood Cancer. 2013 Dec; 60(12):2047-53.
    View on PubMed
  7. Sharib J, Horvai A, Gray Hazard FK, Daldrup-Link H, Goldsby R, Marina N, Dubois SG. Comparison of latino and non-Latino patients with Ewing sarcoma. Pediatr Blood Cancer. 2014 Feb; 61(2):233-7.
    View on PubMed
  8. Thampi S, Matthay KK, Goldsby R, DuBois SG. Adverse impact of regional lymph node involvement in osteosarcoma. Eur J Cancer. 2013 Nov; 49(16):3471-6.
    View on PubMed
  9. Thampi S, Hetts SW, Cooke DL, Stewart PJ, Robbins E, Banerjee A, Dubois SG, Char D, Halbach V, Matthay K. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Clin Ophthalmol. 2013; 7:981-9.
    View on PubMed
  10. Wong T, Matthay KK, Boscardin WJ, Hawkins RA, Brakeman PR, DuBois SG. Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2013 Sep; 60(9):1424-30.
    View on PubMed
  11. DuBois SG, Matthay KK. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging. 2013 Mar; 57(1):53-65.
    View on PubMed
  12. Tasian SK, Kim GE, Miniati DN, DuBois SG. Development of anaplastic Wilms tumor and subsequent relapse in a child with diaphanospondylodysostosis. J Pediatr Hematol Oncol. 2012 Oct; 34(7):548-51.
    View on PubMed
  13. French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013 May; 60(5):879-84.
    View on PubMed
  14. Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, London WB, Kreissman S, Baker D, Attiyeh E, Hogarty MD, Maris JM, Giacomini K, Matthay KK. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012; 2012:250834.
    View on PubMed
  15. Karski EE, Matthay KK, Neuhaus JM, Goldsby RE, Dubois SG. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2013 Feb; 37(1):29-33.
    View on PubMed
  16. Applebaum MA, Goldsby R, Neuhaus J, DuBois SG. Clinical features and outcomes in patients with secondary Ewing sarcoma. Pediatr Blood Cancer. 2013 Apr; 60(4):611-5.
    View on PubMed
  17. Applebaum MA, Sambrano E, Lee S, Goldsby R, Matthay KK, DuBois SG. Evaluation of plasma annexin V levels in children and young adults with solid tumors. Int J Biol Markers. 2012 Apr-Jun; 27(2):e164-6.
    View on PubMed
  18. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012 Jul; 53(7):1155-63.
    View on PubMed
  19. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 1; 118(23):5894-902.
    View on PubMed
  20. Porzig A, Matthay KK, Dubois S, Pampaloni M, Damon L, Hawkins R, Goldsby R, Hollinger F, Fitzgerald P. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42.
    View on PubMed

Go to UCSF Profiles, powered by CTSI